News & Events

• Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
  Published on 2021-11-30
• Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
  Published on 2021-11-24
• Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
  Published on 2021-11-10
• Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
  Published on 2021-11-10
• Alveolus Bio Joins Microbiome Therapeutics Innovation Group
  Published on 2021-11-09
• Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021
  Published on 2021-11-04
• Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
  Published on 2021-10-26
• Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
  Published on 2021-10-14
• Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
  Published on 2021-10-05
• Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
  Published on 2021-10-02
• Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
  Published on 2021-09-30
• Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
  Published on 2021-09-30
• Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
  Published on 2021-09-29
• Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection
  Published on 2021-09-15
• Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Evaluation and Plan of a Prototype MICROBIOME HEALTH INDEX™ (MHI™)
  Published on 2021-09-08